22/11/2009 (Agence Europe) - The European Medicines Agency has reviewed further information on the centrally authorised H1N1 flu pandemic vaccines Celvapan, Focetria and Pandemrix. The data on Focetria and Pandemrix indicate that a single dose of these vaccines is able to trigger an immune response that may be sufficient to give protection against the H1N1 pandemic influenza in some age groups. For both vaccines, a single dose may be used in adults aged between 18 and 60 years and in children and adolescents (from the age of 9 years for Focetria, and from 10 years for Pandemrix). Pandemrix may also be used as a single dose in the elderly. EMEA continues to recommend two doses for young children and immuno-compromised patients. Information about Celvapan is still being assessed. EMEA recommends that Focetria and Pandemrix can be co-administered with seasonal flu vaccines. EMEA says that some 5 million people have been vaccinated against H1N1 in the EU with only moderate side effects reported to date. (O.J./transl.fl)